Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Oct 28, 2024
Deals
In $1.4B Aliada buy, AbbVie sees value in CNS delivery tech, as well as lead asset
Together, blood-brain barrier transport technology and Phase I Alzheimer’s therapy drive rare 10-figure early-stage takeout
Read More
BioCentury
|
Mar 1, 2022
Deals
VCs gain exit as AbbVie buys UCB neuro spinout Syndesi
With Syndesi takeout, AbbVie gains clinical molecule designed to improve cognitive function
Read More
BioCentury
|
Jan 19, 2022
Deals
UCB pads epilepsy portfolio with $1.9B Zogenix takeout
With UCB patent cliff looming, Zogenix takeout comes ahead of possible Fintepla label expansion
Read More
BioCentury
|
Aug 18, 2018
Regulation
Pediatric push
Why companies should invest in data, alliances to support pediatric extrapolation
Read More
BioCentury
|
Apr 27, 2018
Company News
UCB buys rights to seizure candidate
Read More
BioCentury
|
Apr 20, 2018
Company News
UCB buys rights to seizure candidate
Read More
BioCentury
|
Mar 29, 2018
Emerging Company Profile
Strengthening synapses
How Syndesi’s
SV2A
modulators may restore function to more synapses in AD
Read More
BioCentury
|
Mar 2, 2018
Product R&D
Sigma for synapses
How Cognition plans to protect synapse function in AD via sigma-2
Read More
BioCentury
|
Feb 2, 2018
Financial News
UCB spinout Syndesi raises €17M series A
Read More
BioCentury
|
Feb 3, 2017
Clinical News
Briviact regulatory update
Read More
Items per page:
10
1 - 10 of 87